首页 | 本学科首页   官方微博 | 高级检索  
检索        


CB1 Receptor Blockade and its Impact on Cardiometabolic Risk Factors: Overview of the RIO Programme with Rimonabant
Authors:A J Scheen
Institution:Division of Diabetes, Nutrition and Metabolic Disorders and Clinical Pharmacology Unit, CHU Sart Tilman, University of Liege, Liege, Belgium.
Abstract:
Keywords:endocannabinoid system  cardiometabolic risk  CB1 receptor  obesity  rimonabant  type 2 diabetes
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号